Company Overview
Glaxo Group Limited is listed at the official companies registry as Active Private Limited Company. The company was incorporated on Monday 14 October 1935, so this is a well established company. Glaxo Group Limited has been in business for 90 years and 6 months. The accounts status is full and the accounts are next due on Wednesday 30 September 2026.
Registered Address

Gsk Medicines Research Centre, Gunnels Wood Road, Stevenage, SG1 2NY
Credit Reports Available

These credit rating reports are available now:


Credit Analysts Report
Get Report >>

Standard Credit Report
Get Report >>

Basic Credit Report
Get Report >>

24/7 credit rating data feed - no UK company credit reports are updated faster

Companies House Data
Company NameGLAXO GROUP LIMITED
Company Number00305979
Registered Office AddressGsk Medicines Research Centre
 Gunnels Wood Road
 SG1 2NY
Company CategoryPrivate Limited Company
Company StatusActive
Country of OriginUnited Kingdom
Incorporation Date14/10/1935
Accounting Reference Date Day31
Accounting Reference Date Month12
Accounts Next Due Date30/09/2026
Accounts Last Made Up Date31/12/2024
Accounts Account CategoryFULL
Returns Next Due Date12/09/2016
Returns Last Made Up Date15/08/2015
Directors & Members
Show Resigned
Adam Walker - Director
(British, 59 years old, born November 1967)
Appointed 01 October 2015
Active
Edinburgh Pharmaceutical Industries Limited - Director
Appointed 31 January 2001
Active
The Wellcome Foundation Limited - Director
Appointed 05 March 2002
Active
Secretaries
Show Resigned
Victoria Whyte - Secretary
(British)
Appointed 06 June 2001
Active
Other Company Directorships
Adam Walker
ACTION POTENTIAL VENTURE CAPITAL LIMITED
BEECHAM GROUP PLC
DEALCYBER LIMITED
GLAXOCHEM PTE LTD
GLAXOSMITHKLINE CARIBBEAN LIMITED
GLAXOSMITHKLINE EXPORT LIMITED
GLAXOSMITHKLINE FINANCE PLC
GLAXOSMITHKLINE HOLDINGS (IRELAND) LIMITED
GLAXOSMITHKLINE HOLDINGS (ONE) LIMITED
GLAXOSMITHKLINE IHC LIMITED
GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED
GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED
GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.5) LIMITED
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
GLAXOSMITHKLINE INTELLECTUAL PROPERTY HOLDINGS LIMITED
GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED
GLAXOSMITHKLINE INTELLECTUAL PROPERTY MANAGEMENT LIMITED
GLAXOSMITHKLINE INVESTMENT HOLDINGS LIMITED
GLAXOSMITHKLINE INVESTMENT SERVICES LIMITED
GLAXOSMITHKLINE SERVICES UNLIMITED
GSK CAPITAL B.V.
GSK FINANCE (NO 2) LIMITED
GSK GP 1 LIMITED
GSK GP 2 LIMITED
GSK LP LIMITED
HALEON UK HOLDINGS LIMITED
SETFIRST LIMITED
SMITHKLINE BEECHAM (EXPORT) LIMITED
SMITHKLINE BEECHAM (H) LIMITED
SMITHKLINE BEECHAM (INVESTMENTS) LIMITED
SMITHKLINE BEECHAM LEGACY H LIMITED
SMITHKLINE BEECHAM LIMITED
SMITHKLINE BEECHAM MARKETING AND TECHNICAL SERVICES LIMITED
Edinburgh Pharmaceutical Industries Limited
ACTION POTENTIAL VENTURE CAPITAL LIMITED
AIOLOS BIO LIMITED
GALVANI BIOELECTRONICS LIMITED
GLAXO OPERATIONS UK LIMITED
GLAXOSMITHKLINE CONSUMER HEALTHCARE INVESTMENTS (IRELAND) (NO 3) LIMITED
GLAXOSMITHKLINE CONSUMER HEALTHCARE INVESTMENTS (IRELAND) (NO.2) UNLIMITED COMPANY
GLAXOSMITHKLINE CONSUMER HEALTHCARE INVESTMENTS (IRELAND) LIMITED
GLAXOSMITHKLINE CONSUMER HEALTHCARE IRELAND IP LIMITED
GLAXOSMITHKLINE HOLDINGS (IRELAND) LIMITED
GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED
GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED
GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.5) LIMITED
GLAXOSMITHKLINE INTELLECTUAL PROPERTY MANAGEMENT LIMITED
GLAXOSMITHKLINE INVESTMENTS (IRELAND) LIMITED
GLAXOSMITHKLINE LIMITED
GLAXOSMITHKLINE TRADING SERVICES LIMITED
GLAXOSMITHKLINE US TRADING LIMITED
GSK FINANCE (NO 2) LIMITED
GSK FINANCE (NO.3) LIMITED
GSK GP 1 LIMITED
GSK GP 2 LIMITED
GSK LP LIMITED
SETFIRST HOLDINGS LIMITED
TESARO UK LIMITED
VIIV HEALTHCARE FINANCE 2 LIMITED
VIIV HEALTHCARE UK (NO.7) LIMITED
The Wellcome Foundation Limited
ACTION POTENTIAL VENTURE CAPITAL LIMITED
CORPORATE HEALTH AND PERFORMANCE
EDINBURGH PHARMACEUTICAL INDUSTRIES LIMITED
GLAXOSMITHKLINE CONSUMER HEALTHCARE (UK) (NO.1) LIMITED
GLAXOSMITHKLINE FINANCE PLC
GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED
GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED
GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.5) LIMITED
GLAXOSMITHKLINE INTELLECTUAL PROPERTY MANAGEMENT LIMITED
GLAXOSMITHKLINE US TRADING LIMITED
GSK CONSUMER HEALTHCARE HOLDINGS (NO.5) LIMITED
GSK CONSUMER HEALTHCARE HOLDINGS (NO.6) LIMITED
GSK FINANCE (NO 2) LIMITED
GSK FINANCE (NO.3) LIMITED
HALEON UK CORPORATE DIRECTOR LIMITED
HALEON UK CORPORATE SECRETARY LIMITED
HALEON UK FINANCE (USD) LIMITED
HALEON UK HOLDING SRI LANKA LIMITED
HALEON UK HOLDINGS (NO.1) LIMITED
HALEON UK HOLDINGS (NO.3) LIMITED
HALEON UK HOLDINGS (NO.7) LIMITED
HALEON UK HOLDINGS LIMITED
HALEON UK IP (NO. 2) LIMITED
HALEON UK IP LIMITED
HALEON UK SERVICES LIMITED
HALEON UK TRADING LIMITED
MONTROSE FINE CHEMICAL COMPANY LTD.
SMITHKLINE BEECHAM LIMITED
Balance Sheet Unlock full report
Accounts Date 31-Dec-2024 31-Dec-2010 31-Dec-2009
Balance Sheet
Fixed Assets 5,279,824,000 5,279,824,000 5,460,360,000
Current Assets 1,534,733,000 1,534,733,000 2,797,262,000
Creditors Due Within One Year 1,704,405,000 1,704,405,000 2,052,480,000
Working Cap -169,672,000 -169,672,000 744,782,000
Total Assets Less Current Liabilities 5,110,152,000 5,110,152,000 6,205,142,000
Long-term Liabilities 1,348,650,000 1,348,650,000 950,967,000
Net Assets 3,761,502,000 3,761,502,000 5,254,175,000
Share Capital & Reserves
Share Cap 808,994,000 808,994,000 808,994,000
Profit & Loss Reserves 222,206,000 222,206,000 1,714,879,000
Other Reserves 2,730,302,000 2,730,302,000 2,730,302,000
Shareholders Funds 3,761,502,000 3,761,502,000 5,254,175,000
Common Size Financial Analysis Unlock full report
Accounts Date 31-Dec-2024 31-Dec-2010 31-Dec-2009
Tangible Fixed Assets - - -
Fixed Assets 77.5% 77.5% 66.1%
Stocks Inventory 0.0% 0.0% 0.0%
Debtors 22.5% 22.5% 33.9%
Cash Bank In Hand 0.0% 0.0% 0.0%
Current Assets 22.5% 22.5% 33.9%
Creditors Due Within One Year 25.0% 25.0% 24.9%
Net Current Assets Liabilities -2.5% -2.5% 9.0%
Creditors Due After One Year 0.9% 0.9% 1.2%
Accruals Deferred Income - - -
Provisions For Liabilities Charges - - -
Net Assets Liabilities Including Pension Asset Liability 55.2% 55.2% 63.6%
Called Up Share Capital 11.9% 11.9% 9.8%
Share Capital Allotted Called Up Paid 11.9% 11.9% 9.8%
Profit Loss Account Reserve 3.3% 3.3% 20.8%
Shareholder Funds 55.2% 55.2% 63.6%
Capital Employed - - -
Total Assets Less Current Liabilities 75.0% 75.0% 75.1%
Financial Ratio Analysis Unlock full report
Accounts Date 31-Dec-2024 31-Dec-2010 31-Dec-2009
Liquidity Ratio 0.9 0.9 1.4
Solvency Ratio 2.2 2.2 2.7
Reserves to Assets 0.0 0.0 0.2
Secured Creditors Unlock full report
Mortgages Charges 1
Mortgages Outstanding 0
Mortgages Part Satisfied 0
Mortgages Satisfied 1
Assets and Debt Analysis Unlock full report
Accounts Date 31-Dec-2024 31-Dec-2010 31-Dec-2009
Assets 6,814,557,000 6,814,557,000 8,257,622,000
Debt 3,053,055,000 3,053,055,000 3,003,447,000
Net Assets/Debt 3,761,502,000 3,761,502,000 5,254,175,000

The following is based on the accounts data presented in this report sourced from Companies House, however the company has filed later accounts. Our analysis of the latest account can be viewed by unlocking our full report.

As at the balance sheet date current liquid assets were slightly less than short term debt. We would normally view a company broadly neutrally for this. Total reserves including retained profitability and movement in reserves has some deficiency. The balance sheet indicates the substantial net assets of a large company. For the size of the company inferred by the balance sheet the level of net assets suggests a comfortable level of cover for total debts and obligations.

Unlock full report  The following is based on the accounts data presented in this report sourced from Companies House, however the company has filed later accounts. Our analysis of the latest account can be viewed by unlocking our full report.As at the balance sheet date current liquid assets were slightly less than short term debt. We would normally view a company broadly neutrally for this. Total reserves including retained profitability and movement in reserves has some deficiency. The balance sheet indicates the substantial net assets of a large company. For the size of the company inferred by the balance sheet the level of net assets suggests a comfortable level of cover for total debts and obligations.   The following is based on the accounts data presented in this report sourced from Companies House, however the company has filed later accounts. Our analysis of the latest account can be viewed by unlocking our full report.As at the balance sheet date current liquid assets were slightly less than short term debt. We would normally view a company broadly neutrally for this. Total reserves including retained profitability and movement in reserves has some deficiency. The balance sheet indicates the substantial net assets of a large company. For the size of the company inferred by the balance sheet the level of net assets suggests a comfortable level of cover for total debts and obligations.

This review of public record balance sheet and company status information is presented under the terms of Open Government Licence and is for informational purposes only, is general in nature, and is not intended as an opinion or advice for any specific circumstances. The commentary and the colour band score is not a credit rating or credit risk assessment.

This review does not constitute a full credit rating or credit risk assessment based on the full analysis and credit score algorithms used in our credit reports. A full credit report may also provide information relating to trade payment history and county court or court judgments if any.

Public Record Information Unlock full report
Exact Court Judgements
Period of Months Last 12m 13-24m 25-36m 37-48m 49-60m 61-72m
Number of Exact CCJS X Y Y X X Y
Value of Exact CCJS YXY YK S S X KX
Supplier Credit Limits Unlock full report
Date Sector Notified Amount Terms
XK-SXY XKXYXK SXSKXYXK £X,000 XS XYSKS
SK-SYY SKXYXKYKKY KSXX KKXXYXS £YY,000 YS XYSKS SK YXXSXS
YK-SXY XKXYXYYK SXSXYXK £SX,000 XS XYSKS
Payment Records Unlock full report
Payment Records from it's suppliers' company ledger show how a company is paying its suppliers

Payment Analysis

Total Invoices Paid Before
30 days due
Paid After
30 days due
Owing Before
30 days due
Owing after
30 days due
XYX SX K YX X
Company Valuation Analysis Unlock full report

Going Concern Valuation

The going concern valuations value the company on the basis that it continues to trade without the threat of liquidation for the foreseeable future. These valuations are primarily profit and cashflow based.

Valuations Valuation Measures
Estimated High Value £XSI,000 Retained Profit £YX,000
Estimated Mid Value £YY,000 EBIT £SY,000
Estimated Low Value £X,000 EBITDA £SSX,000

Liquidation Valuation

The liquidaton valuation values the company as if it were to cease trading and assets were subject to rapid disposal to cover liabilities. This valuation is primarily asset based.

Valuations Valuation Measures
Estimated High Value £XY,000 Total Assets £XIX,000
Estimated Mid Value £Y,000 Net Assets £YX,000
Estimated Low Value £S,000 Tangible Equity £SX,000

The above valuations are based on our own algorithms and take no account of many factors that can influence actual valuations realized and should not therefore be assumed to be accurate.

Credit Status Checklist Unlock full report
Business Growth Please purchase a report to see true comments
EBITDA Purchase a report to see true comments
Dividends Please purchase a report to see true comments about this company
Retained Profits Retained Profits for this company
Debt Interest Debt Interest for this company
Cash Flow Cash Flow for this company
CCJs CCJs for this company
Age of Company Age of Company for this company
Solvency Solvency for this company
Secured Creditors Secured Creditors for this company
Ownership Ownership for this company


First Report Score: (0-10) X
Financial Status Guide:
10 Very Strong
9 Strong
8 Very Good
7 Good
6 Above Average
5 Average
4 Below Average
3 Poor
2 Weak
1 Very Weak
0 Critical

Risk Score Trend

Risk Rating Unlock full report

This is the credit risk assessment used by one of the top UK credit reference agencies.

Risk Score (1-100) X
Risk Band Description XXMXMXMX SISX
Risk Assessment Meeting of Creditors
Credit Rating XSKX
Altman Z Score Credit Risk Rating Unlock full report

There have been many bankruptcy predictors developed, however none has been so thoroughly tested and broadly accepted as the Altman Z-Score.

Z Score X
Risk Band XY
Risk Band Description The Z Score is not used for small companies where full accounts are not filed because profit and loss account items are required to calculate the score.

Z Score Bands

1 Low Risk 3.00 and above
2 Caution 2.63 - 2.99
3 Risk of Failure within 2 years 1.24 - 2.62
4 High Probability Failure Below 1.24
Other Business around SG1 2NY
No other companies found in the same location
Document Filings
Confirmation statement made on 31 March 2026 with no updates
Confirmation statement made on 30 July 2025 with no updates
Termination of appointment of Julie Belita Brown as a director on 19 July 2025
Director's details changed for Mrs Julie Belita Brown on 11 September 2024
Secretary's details changed for Mrs Victoria Anne Whyte on 11 September 2024
Director's details changed for Mr Adam Walker on 11 September 2024
Director's details changed for The Wellcome Foundation Limited on 11 September 2024
Change of details for Glaxosmithkline Finance Plc as a person with significant control on 11 September 2024
Confirmation statement made on 15 August 2024 with no updates
Register inspection address has been changed from 980 Great West Road Brentford Middlesex TW8 9GS United Kingdom to 79 New Oxford Street London WC1A 1DG
Confirmation statement made on 15 August 2023 with no updates
Register inspection address has been changed to 980 Great West Road Brentford Middlesex TW8 9GS
Registered office address changed from 980 Great West Road Brentford Middlesex TW8 9GS to Gsk Medicines Research Centre Gunnels Wood Road Stevenage SG1 2NY on 6 June 2023
Appointment of Mrs Julie Belita Brown as a director on 1 May 2023
Termination of appointment of Iain James Mackay as a director on 1 May 2023
Confirmation statement made on 10 August 2022 with no updates
Memorandum and Articles of Association
Resolutions
Resolutions
Statement of Company's objects

In using this service you agree to the Terms and Conditions

© 2026 Check Free